# Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell Transplant

> **NCT04908735** · PHASE2 · TERMINATED · sponsor: **Children's Hospital Medical Center, Cincinnati** · enrollment: 7 (actual)

## Conditions studied

- Hematopoietic Stem Cell Transplant (HSCT)
- Bronchiolitis Obliterans (BO)

## Interventions

- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT04908735
- **Lead sponsor:** Children's Hospital Medical Center, Cincinnati
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-11-12
- **Primary completion:** 2025-09-17
- **Final completion:** 2025-11-16
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Study closed due to slow enrollment.
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04908735

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04908735, "Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell Transplant". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT04908735. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*